PM — Q2 2026 Financial Report Analysis

A $511 million write-down on Canada masks the strongest operating quarter PMI has posted in years

Philip Morris International's reported earnings per share fell 7.7% in the second quarter of 2026, to $1.80 from $1.95. Almost nothing about that number describes the underlying business. Net revenues rose 10.4% to $11.19 billion and operating income — profit from actually selling products, before interest, tax and investment gains — rose 22.0% to $4.53 billion, lifting the operating margin nearly four percentage points to 40.5%. The gap between the two is a single non-cash charge: a $511 million impairment of PMI's stake in Rothmans, Benson & Hedges (RBH), its deconsolidated Canadian subsidiary, worth $0.33 per share. Strip that and the other accounting adjustments out and PMI's own adjusted EPS measure was $2.20, up 15.2%.

Takeaway: The reported EPS decline is an accounting event in a business PMI has not controlled since 2019; the operating result underneath it — 7.6% organic revenue growth and a 3.9-point margin expansion — is the number that matters. The genuine warning sign in this filing is not Canada but the United States, where ZYN's shipment growth has stalled at 1.8% and segment revenue actually fell.

What the RBH charge is, and why it is not a business event

PMI deconsolidated RBH in March 2019, when the Ontario Superior Court granted the Canadian unit protection under the Companies' Creditors Arrangement Act — Canada's corporate restructuring regime — amid tobacco litigation. Deconsolidation means RBH's revenues and profits stopped flowing into PMI's income statement; what remains is a carrying value for the equity stake on PMI's balance sheet. A court-approved settlement plan took effect in August 2025, but PMI concluded that the powers the plan grants RBH's Plan Administrator still deprive PMI of control, so RBH stays deconsolidated.

In May 2026 RBH delivered its required annual business plan to the Plan Administrator, with updated five-year projections "reflecting current industry dynamics." Those projections implied a fair value below the carrying value, so PMI wrote the stake down by $511 million. The carrying value is now $51 million, from $569 million at the end of 2025 — cumulative impairments and downward adjustments on the investment reach $3.06 billion. In cash terms this quarter, the charge is zero. What it does signal is that PMI now assigns almost no residual value to its Canadian position: at $51 million there is very little left to write off, which removes this line as a recurring source of earnings noise going forward.

A second, smaller drag on reported earnings was genuine: equity investment income fell to $159 million from $376 million, on fair-value swings in PMI's Indian and Sri Lankan holdings, and the effective tax rate rose 3.3 points to 22.3%. Interest expense went the other way, down 12.3% to $243 million on higher interest income.

Growth came from price, not volume — except in smoke-free

Of the 10.4% revenue increase, 7.6 points were organic — that is, excluding currency movements and acquisitions or disposals. The remaining ~2.8 points were a currency tailwind, mainly a stronger euro and Russian ruble, partly offset by a weaker Japanese yen. Management attributes the organic gain chiefly to "a favorable pricing variance mainly driven by international combustibles," supported by international smoke-free volume.

That combustibles line deserves attention, because it is where the quarter's profit growth was actually manufactured. International combustibles net revenues rose 9.8% (6.4% organic) on what PMI itself calls "an exceptional quarter of 10.0% pricing" — a double-digit price increase carried with cigarette volume up 1.1%, driven by Turkey, Indonesia and Egypt. Marlboro's share of the cigarette category rose 0.3 points to a record-matching 11.0%. Pricing at that level on a still-growing volume base is not the usual shape of a declining category, and it is the reason gross margin expanded to 68.4% from 67.7%. The offset is geographic mix: growth is concentrated in developing markets with lower revenue per unit, which is why the 9.8% reported revenue gain converts to only 6.4% organic.

International smoke-free revenue rose 14.2% (11.8% organic) on 8.0% volume growth to 44.7 billion units. Within that:

• IQOS (heat-not-burn): shipment volumes +7.6%; share of combined cigarette and heated-tobacco industry volume up 0.2 points to 9.2% where PMI operates. Adjusted in-market sales — units actually bought by consumers, rather than shipped to distributors — grew only 5.1%, held back by two identified one-offs: Japanese retailers and consumers working down stockpiles after an April 1 excise-driven price increase (PMI estimates Japanese IMS fell 3.4%, but rose 1.0% excluding the de-loading effect), and Poland's ban on characterizing flavors. Excluding Japan and Poland, adjusted IMS grew roughly 10%. Both headwinds are dated and identifiable, which makes the 10% the better read on the underlying trend — though the Polish flavor ban is a permanent regulatory reset, not a timing item that reverses.
• VEEV (e-vapor): shipments +55.1%, off a small base, now the leading closed-pod product in Europe.
• Oral: the weak spot internationally. Modern oral (nicotine pouch) volumes grew 14.7% — 26.3% excluding the Nordics — but continued decline in the legacy Nordic snus business pulled total oral shipment volume down 7.0%.

The U.S. segment is the problem the filing half-buries

U.S. net revenues fell 0.7% year on year (−0.9% organic). ZYN shipments rose just 1.8% to 2.9 billion pouches, and PMI concedes that consumer offtake was "flat to slightly growing versus the prior year in a growing category" — meaning ZYN is losing share — which it attributes to "the uneven competitive landscape," its shorthand for rivals selling flavored pouches that PMI says are not lawfully marketed. Cigars declined and Wellness revenue was hurt by shipment phasing.

The half-year picture is worse than the quarter and shows why: six-month U.S. smoke-free revenue was $1,311 million against $1,584 million, down 17.2% (−16.5% organic), almost all of it incurred in the first quarter when distributor and trade inventory movements reversed and a light prior-year promotional comparison made pricing look unfavorable. Q2 was a sequential recovery, but recovery to roughly flat. Six-month U.S. gross profit fell 27.5% organically, hit additionally by higher manufacturing costs from capacity expansion; Q2 adjusted operating income for the segment fell 19.1% organically to $279 million.

PMI's response is portfolio widening rather than price defense: ZYN ULTRA (9mg and 11mg moist variants at a lower price per pouch) began shipping in June, with 1.5mg and 8mg dry variants due in Q3, and the company intends to "accelerate U.S. investments in the second half." On June 30 the FDA granted modified-risk authorization to 20 ZYN variants — the first for any nicotine pouch. That is a durable regulatory advantage, but it did not stop share erosion this quarter, and a cheaper ZYN tier plus higher spending means the U.S. segment's margin gets worse before it gets better.

Guidance and outlook

Management raised reported diluted EPS guidance to $7.19–$7.34 for full-year 2026 and holds adjusted diluted EPS at $8.26–$8.41, growth of 9.5%–11.5% over 2025's $7.54. The change was explicitly currency-only: the assumed favorable FX contribution fell to $0.15 from $0.20, because Q2's better-than-expected transactional gains are more than offset by the translation effect of a stronger dollar. Excluding currency, the range implies 7.5%–9.5% growth. Other assumptions: organic net revenue growth of 5%–7%, organic operating income growth of 7%–9%, an effective tax rate near 21.5%, operating cash flow around $13.5 billion, capital expenditure of $1.4–$1.6 billion, net debt to adjusted EBITDA near 2.0x by year-end, and no share repurchases. Q3 adjusted diluted EPS is guided to $2.20–$2.25, including an estimated 8-cent currency headwind.

Two things stand out against that frame. First, first-half organic revenue growth of 5.3% sits at the bottom of the 5%–7% full-year range while H1 organic operating income growth of 6.1% sits below the 7%–9% range — so the guidance requires second-half acceleration, which has to come from combustibles pricing persisting and from the U.S. stabilizing rather than from a new driver. Second, the quality of this quarter's earnings is better than the 22% operating income growth suggests in one respect and worse in another: $237 million of the improvement is simply the absence of the prior year's restructuring charges ($6 million in Q2 2026 versus $243 million in Q2 2025), which flatters the comparison, while the pricing that drove the rest is real and recurring.

Cash generation is the strongest supporting evidence for the bull case: first-half operating cash flow of $5.1 billion against $3.1 billion a year earlier, $1.5 billion of the improvement from lower working capital. That funds the deleveraging target without buybacks.

Our read: the operating business is performing better than the reported EPS line and roughly in line with the adjusted one, and the combustibles pricing power is the underappreciated engine — 10% price on flat-to-growing volume is what is paying for smoke-free expansion. The risk is not Canada and not Japan; it is that ZYN's U.S. share loss turns into a price war in the category PMI was supposed to own outright, at the same time as heated tobacco absorbs permanent flavor-ban restrictions in Europe. Neither is visible in the 2026 guidance. Both would show up in 2027.